Adc Therapeutics SA [NYSE: ADCT] slipped around -0.65 points on Wednesday, while shares priced at $3.95 at the close of the session, down -14.13%.
Adc Therapeutics SA stock is now 63.22% up from its year-to-date (YTD) trading value. ADCT Stock saw the intraday high of $4.55 and lowest of $2.94 per share. The company’s 52-week high price is 4.80, which means current price is +276.19% above from all time high which was touched on 10/30/25.
Compared to the average trading volume of 891.51K shares, ADCT reached a trading volume of 11542194 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Adc Therapeutics SA [ADCT]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ADCT shares is $8.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ADCT stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Stephens have made an estimate for Adc Therapeutics SA shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on November 08, 2024. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Overweight. The new note on the price target was released on May 30, 2024, representing the official price target for Adc Therapeutics SA stock. Previously, the target price had yet another raise to $11, while Guggenheim analysts kept a Buy rating on ADCT stock.
How has ADCT stock performed recently?
Adc Therapeutics SA [ADCT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -10.02. With this latest performance, ADCT shares dropped by -5.50% in over the last four-week period, additionally plugging by 18.26% over the last 6 months – not to mention a rise of 98.49% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ADCT stock in for the last two-week period is set at 44.60, with the RSI for the last a single of trading hit 0.41, and the three-weeks RSI is set at 0.33 for Adc Therapeutics SA [ADCT]. The present Moving Average for the last 50 days of trading for this stock 4.16, while it was recorded at 4.28 for the last single week of trading, and 2.85 for the last 200 days.
Adc Therapeutics SA [ADCT]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Adc Therapeutics SA [ADCT] shares currently have an operating margin of -162.94% and a Gross Margin at 89.33%. Adc Therapeutics SA’s Net Margin is presently recorded at -221.97%.
Adc Therapeutics SA (ADCT) Capital Structure & Debt Analysis
Adc Therapeutics SA (ADCT) Efficiency & Liquidity Metrics
Adc Therapeutics SA (ADCT) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Adc Therapeutics SA. (ADCT) effectively leverages its workforce, generating an average of -$629962.26 per employee. The company’s liquidity position is robust, with a Current Ratio of 4.63% and a Quick Ratio of 4.34%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Adc Therapeutics SA [ADCT]
With the latest financial reports released by the company, Adc Therapeutics SA posted -0.29/share EPS, while the average EPS was predicted by analysts to be reported at -0.41/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.12. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ADCT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Adc Therapeutics SA go to 21.36%.
Insider trade positions for Adc Therapeutics SA [ADCT]
There are presently around $58.60%, or 68.17%% of ADCT stock, in the hands of institutional investors. The top three institutional holders of ADCT stocks are: REDMILE GROUP, LLC with ownership of 15.27 million shares, which is approximately 15.9568%. PROSIGHT MANAGEMENT, LP, holding 9.57 million shares of the stock with an approximate value of $$30.24 million in ADCT stocks shares; and PROSIGHT MANAGEMENT, LP, currently with $$13.64 million in ADCT stock with ownership which is approximately 4.5112%.
